---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-026397"
form_type: "8-K"
ticker: "ZVRA"
cik: "0001434647"
company_name: "ZEVRA THERAPEUTICS, INC."
filed_at: "2024-08-13T23:59:59+00:00"
generated_at: "2026-05-31T09:40:31.638432+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Zevra Q2 revenue falls to $4.4M, net loss $19.9M; FDA decision on arimoclomol by Sept 21

## Summary
- Net revenue $4.4M vs $8.5M YoY; net loss $19.9M ($0.48/share) vs $2.6M ($0.08/share) in Q2 2023.
- FDA advisory committee voted arimoclomol effective for NPC; PDUFA target action date Sept 21, 2024.
- Pro-forma cash $113.8M after $64.5M net from August public offering; cash runway into Q1 2027.
- OLPRUVA added 9 new patient enrollments in Q2; reimbursement coverage expanded to 75% of covered lives.
- Refinanced debt with $100M credit facility from Perceptive Advisors and HCR; initial draw $60M.

## SEC filing metadata
- accession: 0001437749-24-026397
- form_type: 8-K
- ticker: ZVRA
- cik: 0001434647
- company_name: ZEVRA THERAPEUTICS, INC.
- filed_at: 2024-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434647/000143774924026397/0001437749-24-026397-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434647/000143774924026397/zvra20240520_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-026397
- JSON: https://secwatch.observer/filing/0001437749-24-026397.json
- Plain text: https://secwatch.observer/filing/0001437749-24-026397.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.